It operates in the world of health and science. It has 5 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Average growth of 6% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
Executives buying with their own money is usually read as confidence in the company’s future.
An investor who bought at the very peak is down 95% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Sales run at $76K a year. A small number, but proof the product has real buyers.
There is $12.0M in the vault; even if every debt were paid off, $12.0M would remain.
Over the last 12 months, company executives reported 16 buys and 1 sell. Management buying with its own money is usually read as a good sign.
A loss of $7.2M against $76K in annual sales.
The stock sits at $0.04. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
At the current pace of spending, the cash lasts about 1.7 years. After that, the company needs to find new money.
On our five-subject report card, ACONW sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: ACONW is a high-risk stock — not yet profitable, and its future rides on its product catching on.